Esperion Therapeutics (ESPR) said Monday it has submitted New Drug Submissions to Health Canada for Nexletol and Nexlizet, oral non-statin medications designed to lower LDL cholesterol and potentially reduce cardiovascular risks in patients unable to tolerate statins.
The company said the medications are intended for adults with established cardiovascular disease or those at high risk of a cardiovascular event.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.